No Data
Shandong Buchang Pharmaceuticals Terminates Agreements With Nantong Lianya Pharmaceutical
Shandong Buchang Pharmaceuticals (603858.SH): Plans to give up the preferential acquisition of equity in its controlling subsidiaries.
Gelonghui, December 26 - Shandong Buchang Pharmaceuticals (603858.SH) announced that its controlling subsidiary Shanghai Hupu's shareholder Wang Baocai intends to transfer his unpaid 0.05% equity in Shanghai Hupu to Zhao Xiaogang at a transaction price of 0 yuan, and intends to transfer his unpaid 0.025% equity in Shanghai Hupu to Cheng Kai at a transaction price of 0 yuan. The company agrees to waive its preemptive rights, and after the transaction is completed, the company will maintain its 71.30% equity stake in Shanghai Hupu.
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?
Shandong Buchang Pharmaceuticals (603858.SH): Application for clinical trials of the varicella attenuated live vaccine has been accepted.
Shandong Buchang Pharmaceuticals (603858.SH) announced that its controlling subsidiary Zhejiang Tianyuan Biopharmaceutical Co., Ltd.'s "...
Buchang Pharmaceuticals Gets Drug Registration for Donepezil Hydrochloride Tablets
Shandong Buchang Pharmaceuticals (603858.SH): Signed a pharmaceutical registration clinical trial entrustment contract.
Gelonghui December 3rd | Shandong Buchang Pharmaceuticals (603858.SH) announced that the company signed a "Contract Entrusting Beijing Zhuoyue Future International Pharmaceutical Technology Development Co., Ltd." (referred to as "Beijing Zhuoyue") for the registration clinical trial of Shenfu Yixin Granule, entrusting Beijing Zhuoyue to complete the registration clinical trial of Shenfu Yixin Granule. The total price of the registration clinical trial for this project is 55,338,000.00 yuan (including taxes). This time the company signed a "Contract Entrusting Registration Clinical Trial of Shenfu Yixin Granule" with a third party, which is beneficial for expanding the company's pharmaceutical R&D capabilities and scope, to some extent saving the time and cost of the company's pharmaceutical clinical trials.
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
No Data
